Published in Nucleic Acids Res on October 15, 2010
Cancer DNA Screening Pilot Study (CANDACE) (CANDACE) | NCT02808884
An integrated map of genetic variation from 1,092 human genomes. Nature (2012) 59.82
Cancer genome landscapes. Science (2013) 25.33
STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res (2012) 18.26
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res (2012) 13.14
Ensembl 2014. Nucleic Acids Res (2013) 12.62
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Ensembl 2013. Nucleic Acids Res (2012) 11.70
Activities at the Universal Protein Resource (UniProt). Nucleic Acids Res (2013) 11.67
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet (2011) 8.53
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48
A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med (2011) 8.26
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med (2014) 6.89
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet (2014) 6.69
Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature (2013) 6.57
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
Integrated genomic characterization of papillary thyroid carcinoma. Cell (2014) 6.05
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet (2014) 5.74
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet (2011) 5.68
SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics (2011) 5.62
Effect of mutation order on myeloproliferative neoplasms. N Engl J Med (2015) 5.59
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov (2013) 4.39
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med (2011) 4.37
Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature (2012) 4.35
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res (2012) 4.34
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science (2014) 4.28
The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer (2012) 3.75
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Genenames.org: the HGNC resources in 2013. Nucleic Acids Res (2012) 3.69
A comprehensive survey of Ras mutations in cancer. Cancer Res (2012) 3.67
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science (2012) 3.41
The next-generation sequencing revolution and its impact on genomics. Cell (2013) 3.35
JointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal/tumour paired next-generation sequencing data. Bioinformatics (2012) 3.21
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet (2012) 3.19
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med (2014) 3.18
HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science (2014) 3.17
Making sense of cancer genomic data. Genes Dev (2011) 3.01
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood (2012) 2.98
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res (2014) 2.92
Accessing protein conformational ensembles using room-temperature X-ray crystallography. Proc Natl Acad Sci U S A (2011) 2.92
TSGene: a web resource for tumor suppressor genes. Nucleic Acids Res (2012) 2.90
Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature (2014) 2.85
DbVar and DGVa: public archives for genomic structural variation. Nucleic Acids Res (2012) 2.81
Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol (2015) 2.80
Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning. Nat Biotechnol (2015) 2.79
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Ras in cancer and developmental diseases. Genes Cancer (2011) 2.68
Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol Ther (2013) 2.64
POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet (2013) 2.62
Landscape of genomic alterations in cervical carcinomas. Nature (2013) 2.61
The [4Fe4S] cluster of human DNA primase functions as a redox switch using DNA charge transport. Science (2017) 2.60
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol (2013) 2.59
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med (2013) 2.58
Protein arginine methyltransferases and cancer. Nat Rev Cancer (2012) 2.56
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov (2012) 2.48
Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science (2013) 2.46
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 2.41
Functional annotation of noncoding sequence variants. Nat Methods (2014) 2.41
POT1 loss-of-function variants predispose to familial melanoma. Nat Genet (2014) 2.40
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2012) 2.39
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet (2013) 2.38
Annotating cancer variants and anti-cancer therapeutics in reactome. Cancers (Basel) (2012) 2.35
Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab (2013) 2.34
Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res (2013) 2.29
GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics (2013) 2.29
Germline mutations in shelterin complex genes are associated with familial glioma. J Natl Cancer Inst (2014) 2.23
SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood (2013) 2.18
Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet (2014) 2.17
The 2012 Nucleic Acids Research Database Issue and the online Molecular Biology Database Collection. Nucleic Acids Res (2011) 2.16
PDBe: Protein Data Bank in Europe. Nucleic Acids Res (2013) 2.16
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature (2014) 2.11
Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet (2015) 2.10
Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep (2011) 2.09
Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A (2013) 2.09
Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet (2014) 2.08
The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer (2013) 2.05
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol (2013) 2.04
Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell (2015) 2.03
Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis (2013) 2.02
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun (2014) 2.00
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov (2014) 1.99
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol (2015) 1.99
The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell (2014) 1.98
Cancer evolution is associated with pervasive positive selection on globally expressed genes. PLoS Genet (2014) 1.94
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med (2012) 1.90
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The generic genome browser: a building block for a model organism system database. Genome Res (2002) 42.64
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet (2008) 16.09
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res (2009) 9.59
BioMart Central Portal--unified access to biological data. Nucleic Acids Res (2009) 9.06
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
The cancer genome. Nature (2009) 23.13
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59